Cannabis vs Psychedelics: What Really Helps OCD Symptoms

Obsessive-compulsive disorder (OCD) is a difficult and often exhausting condition marked by repeating thoughts and behaviors that feel impossible to control.  While treatments like therapy and medication help many people, approximately 40-60% of patients remain unresponsive and are considered treatment-resistant.  This has led researchers to explore new options, including cannabis and psychedelics.

A recent scientific review¹ looked at the current evidence on how cannabinoids and psychedelic substances might affect OCD symptoms.  The authors found that cannabis may offer short-term relief for some people but lacks strong proof as a long-term treatment, while psychedelics—especially psilocybin—show a stronger signal for efficacy in treatment-resistant OCD.

Below, we look at the findings and explore what this could mean for people living with OCD and other conditions that cannabis and alternative medicines may help.

What Did the Study Examine?

The review covered many types of evidence, including online surveys, case reports, open-label studies, and early clinical trials. The main substances examined were cannabinoids (including THC, CBD, and synthetic versions like dronabinol and nabilone) and psychedelics (such as psilocybin, LSD, DMT, and MDMA).

The key questions were simple: Do these substances reduce obsessions, compulsions, anxiety, or general distress in people with OCD?  And if they do, how strong and lasting are the effects?

What the Research Says About Cannabis and OCD

Short-Term Relief Is Possible

Several observational studies found that some people feel better shortly after using cannabis.  In one app-based study, people who were prescribed medical cannabis rated their symptoms before and after using it. Users reported significant reductions in intrusive thoughts (49%), compulsive behaviors (60%), and anxiety (52%).

However, these benefits appeared to be short-term; while users felt better immediately after use, there was no significant reduction in baseline intrusive thoughts or compulsions over time.

Controlled Studies Are Less Impressive

When researchers tested cannabis more strictly in a controlled lab setting, the results were less encouraging.  In a double-blind trial where people with OCD smoked THC-dominant cannabis, CBD-dominant cannabis, or a placebo, all groups showed some reduction in anxiety and OCD symptoms.

Surprisingly, the placebo group actually had a stronger early drop in anxiety than the THC or CBD groups immediately after administration.  Furthermore, neither cannabis variant significantly affected obsessions or compulsions compared to the placebo.

In simple terms: people felt different after smoking cannabis, but when carefully measured, cannabis did not clearly outperform a fake version in treating the core symptoms.

Synthetic Cannabinoids: Mixed and Very Early Data

There are a few small reports using synthetic cannabinoids.  Some cases of treatment-refractory OCD showed improvement with dronabinol.  In a small trial using nabilone, adding the drug to exposure therapy (ERP) resulted in greater symptom improvement than nabilone alone.  However, some participants withdrew due to prolonged anxiety, and the sample sizes were too small to draw firm conclusions.

Bottom Line for Cannabis and OCD

The review concludes that the current evidence indicates a lack of support for using cannabinoids to treat OCD.  While there are reports of short-term relief, properly powered trials are needed to see if it can be a reliable therapy.

Swipe to scroll →

How People With OCD Use Cannabis Today (And What to Know)

Many people with OCD already use cannabis to cope.  The research suggests a few practical takeaways:

• Short-term calm is possible: Users consistently report immediate reductions in intrusions and anxiety.
• High THC can backfire: In clinical settings, THC was associated with higher heart rates and feelings of “being high” compared to CBD, and in some cases, synthetic cannabinoids caused prolonged anxiety.
• Expectation vs. Reality: The belief that cannabis helps (the “lore” of cannabis utility) often leads to self-medication, even if high-quality evidence is limited.

Psychedelics: A Stronger Signal, Especially for Psilocybin

In contrast to cannabis, the review found a stronger signal for the use of psilocybin in treatment-resistant OCD.

What the Psilocybin Studies Show

• Rapid Results: In preliminary trials, psilocybin produced large decreases in OCD scores within 48 hours.
• Lasting Effects: In one unpublished study, 66.7% of participants maintained at least a 25% reduction in symptoms six months later.  One case study reported a patient feeling “OCD-free” a year after a single dose.
• Low Dose Potential: A recent study found that a modest 10 mg dose significantly reduced compulsive symptoms after one week compared to a 1 mg control, without inducing troubling perceptual abnormalities.

What Might Be Happening in the Brain?

Researchers believe psychedelics may suppress the Default Mode Network (DMN), a brain network linked to self-referential thinking and rumination.  Hyper-connectivity in this network and the cortico-striato-thalamo-cortical (CSTC) loop is thought to sustain obsessive thoughts.

By disrupting these networks, psychedelics may induce a more “entropic” or flexible brain state, allowing patients to break free from rigid behavioral patterns.  They may also promote neuroplasticity—helping the brain form new connections.

Beyond OCD: Verified and Promising Uses

While the review concludes that evidence for treating OCD with these substances is still emerging, the authors noted that both cannabis and psychedelics have established or growing track records for other conditions. Understanding where these treatments are already working can provide important context for their potential future roles.

Cannabis: Proven for Pain and Spasticity

The review highlights that the “lore” of cannabis utility often outpaces the science for mental health conditions, but for physical ailments, the evidence is much stronger. A high-level summary of the literature indicates that the most robust evidence supports the use of cannabis for pain management, specifically for neuropathic and cancer-related pain.

Beyond pain, researchers found strong evidence for its use in treating neurological and physical issues, including intractable epilepsy, spasticity associated with multiple sclerosis, and cancer-related nausea. The plant is also recognized for its ability to stimulate appetite in wasting disorders and assist with inflammatory bowel disorders. While THC is often used for anxiety, specific trials have shown that CBD may offer benefits for social anxiety disorder without the psychoactive risks.

Psilocybin: A “Breakthrough” for Mood and Trauma

The authors note that although psilocybin remains experimental for OCD, it has already shown a strong “signal for efficacy” in several other major psychiatric conditions.  Much of the renewed interest in classic psychedelics comes from their success in three key areas: depression, trauma, and addiction.

Psilocybin is now widely studied as a rapid-acting treatment for depressive disorders, often working through mechanisms different from traditional antidepressants.  It has also shown significant promise alongside MDMA in treating Post-Traumatic Stress Disorder (PTSD), offering relief for patients who have not responded to existing therapies.

Additionally, a growing body of research suggests psychedelics may help disrupt rigid patterns of alcohol or substance consumption, making them a potential tool for treating addiction.

Together, these findings help explain why psilocybin is being explored for conditions characterized by cognitive rigidity and entrenched behavioral loops—patterns that overlap with OCD.

Important Cautions

Despite growing enthusiasm around psychedelic research, the authors stress that the current evidence comes with notable limitations.  Many studies involve small sample sizes and lack adequate control groups, making it difficult to draw firm conclusions about long-term effectiveness.

Additionally, all clinical trials have been conducted in structured environments that include preparation sessions, therapeutic support, and close monitoring—conditions that differ dramatically from recreational use.

Expectation bias is another concern, as participants who believe psychedelics will help may report improvements influenced in part by those beliefs.

Because of these factors, the review concludes that psychedelics cannot yet be recommended as standard treatments for OCD. Still, they remain an intriguing frontier for individuals who have exhausted conventional options without adequate relief.

References:

^{1. Van Ameringen, M., Patel, V., Patterson, B., Hopkinson, P., & Rahat, M. (2026). New treatments for OCD? Evidence for cannabinoids and psychedelics. Journal of Psychiatric Research, 193, 172–178. https://doi.org/10.1016/j.jpsychires.2025.11.021}